EGFR and non-small cell lung carcinoma: In previous clinical studies, it has been confirmed that ginsenoside Rg3 improves median PFS (Progression-Free Survival) and ORR (Objective Response Rate) of first-line EGFR-TKI treatment in patients with EGFR-mutant advanced NSCLC (Non-Small Cell Lung Cancer).